Minimal change disease associated with anti-PD1 immunotherapy: a case report

Minimal change disease associated with anti-PD1 immunotherapy: a case report

Abstract Background Oncologic immunotherapy is a form of therapy intended to reactivate the immune response to tumor cells using agents that modulate immune checkpoints, such as programmed cell death protein 1 and its ligand (PD-1/PD-L), and cytotoxic T-lymphocyte-associated antigen 4. Along with ac...

Full description

Bibliographic Details
Main Authors: Bixia Gao, Ningjing Lin, Suxia Wang, Yu Wang
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Nephrology
Subjects:
Oncologic immunotherapy
Anti-PD1
Nephrotic syndrome
Minimal change disease
Online Access:http://link.springer.com/article/10.1186/s12882-018-0958-6

Internet

http://link.springer.com/article/10.1186/s12882-018-0958-6

Similar Items